We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Peering inside Alzheimer's brains.
- Authors
Gunjan Sinha
- Abstract
The article reports on the progress made in drug development for Alzheimer's disease therapies through advancements made in imaging and biomarker identification. It notes that over the past few years leading to 2011, 11 or more Alzheimer's drugs have posted failures in clinical trials. It adds that despite such failures, advances in imaging such as the radioactive tracer Amyvid from Eli Lilly lead to lesser imaging costs. It is said that biomarkers such as the cerebrospinal fluid biomarkers can help in patient selection for clinical trials.
- Subjects
DRUG development; ALZHEIMER'S disease treatment; BIOMARKERS; CLINICAL trials; RADIOACTIVE tracers; ELI Lilly &; Co.; CEREBROSPINAL fluid; PATIENT selection
- Publication
Nature Biotechnology, 2011, Vol 29, Issue 5, p384
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt.1863